{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-023881","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.013400+00:00","generated_at":"2026-05-15T19:29:25.318065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance","bullets":["Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.","FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.","Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.","Board approved $75M share repurchase program; cash and short-term investments $148.5M.","Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-023881","json":"https://secwatch.observer/filing/0001213900-26-023881.json","markdown":"https://secwatch.observer/filing/0001213900-26-023881.md","text":"https://secwatch.observer/filing/0001213900-26-023881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/0001213900-26-023881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:29:25.318065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}